WP
Woodline Partners Portfolio holdings
AUM
$18.9B
1-Year Return
23.37%
This Quarter Return
+9.42%
1 Year Return
+23.37%
3 Year Return
+125.78%
5 Year Return
+185.63%
10 Year Return
–
AUM
$11.8B
AUM Growth
+$1.41B
(+13%)
Cap. Flow
+$896M
Cap. Flow
% of AUM
7.57%
Top 10 Holdings %
Top 10 Hldgs %
12.15%
Holding
744
New
202
Increased
220
Reduced
152
Closed
160
Top Buys
| 1 |
ASML
ASML
|
+$125M |
| 2 |
Meta Platforms (Facebook)
META
|
+$100M |
| 3 |
STMicroelectronics
STM
|
+$92.5M |
| 4 |
MetLife
MET
|
+$79.4M |
| 5 |
Gilead Sciences
GILD
|
+$77.3M |
Top Sells
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$151M |
| 3 |
Marsh & McLennan
MMC
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$86.7M |
| 5 |
Electronic Arts
EA
|
+$78.6M |
Sector Composition
| 1 | Healthcare | 43.57% |
| 2 | Technology | 17.47% |
| 3 | Industrials | 8.1% |
| 4 | Energy | 6.42% |
| 5 | Financials | 6.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
501
Tenable Holdings
TENB
$3.73B
| $1.14M | 0.01% |
+28,249
| New | +$1.14M |
|
|
IGMS
502
DELISTED
IGM Biosciences
IGMS
| $1.11M | 0.01% |
67,259
-7,741
| -10% | -$128K |
|
|
BBOT
503
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$810M
| $1.08M | 0.01% |
103,247
| – | – |
|
504
Appian
APPN
$2.42B
| $1.07M | 0.01% |
31,373
+6,308
| +25% | +$215K |
|
505
Fractyl Health
GUTS
$68.9M
| $1.06M | 0.01% |
419,975
+160,427
| +62% | +$406K |
|
506
Penumbra
PEN
$11.2B
| $992K | 0.01% |
+5,105
| New | +$992K |
|
507
Reviva Pharmaceuticals
RVPH
$30.4M
| $986K | 0.01% |
684,805
-907,983
| -57% | -$1.31M |
|
508
Alkami Technology
ALKT
$2.66B
| $966K | 0.01% |
30,623
+19,345
| +172% | +$610K |
|
|
ABVX
509
Abivax
ABVX
$6.74B
| $942K | 0.01% |
81,730
+50,446
| +161% | +$581K |
|
510
JFrog
FROG
$5.83B
| $901K | 0.01% |
31,039
+11,170
| +56% | +$324K |
|
511
Apple
AAPL
$3.48T
| $884K | 0.01% |
3,792
-29
| -0.8% | -$6.76K |
|
|
BOW
512
Bowhead Specialty Holdings
BOW
$1.05B
| $868K | 0.01% |
31,000
-31,000
| -50% | -$868K |
|
513
Kiniksa Pharmaceuticals
KNSA
$2.73B
| $850K | 0.01% |
+34,029
| New | +$850K |
|
514
Amplitude
AMPL
$1.51B
| $845K | 0.01% |
94,223
-419
| -0.4% | -$3.76K |
|
515
Manhattan Associates
MANH
$13B
| $830K | 0.01% |
2,949
-64,048
| -96% | -$18M |
|
516
Mersana Therapeutics
MRSN
$38.2M
| $819K | 0.01% |
17,342
-41,350
| -70% | -$1.95M |
|
517
Outlook Therapeutics
OTLK
$41.2M
| $809K | 0.01% |
151,508
+722
| +0.5% | +$3.86K |
|
518
Microsoft
MSFT
$3.7T
| $806K | 0.01% |
1,872
-130,829
| -99% | -$56.3M |
|
519
Aligos Therapeutics
ALGS
$78M
| $796K | 0.01% |
91,971
+70,723
| +333% | +$612K |
|
520
Peabody Energy
BTU
$2.25B
| $791K | 0.01% |
+29,797
| New | +$791K |
|
521
Gossamer Bio
GOSS
$630M
| $777K | 0.01% |
787,288
+5,510
| +0.7% | +$5.44K |
|
522
Regal Rexnord
RRX
$9.45B
| $767K | 0.01% |
4,623
-46,777
| -91% | -$7.76M |
|
523
DocuSign
DOCU
$16B
| $719K | 0.01% |
+11,584
| New | +$719K |
|
524
DoubleVerify
DV
$2.42B
| $707K | 0.01% |
+42,012
| New | +$707K |
|
525
MacroGenics
MGNX
$109M
| $621K | 0.01% |
188,711
-180,831
| -49% | -$595K |
|